Sentinel Lymph Node Biopsy After Preoperative Chemotherapy for Breast Cancer: Findings From the Austrian Sentinel Node Study Group

Tausch, Christoph; Kempler, Péter; Kugler, F.; Reitsamer, Roland; Roka, R.; Pöstlberger, Sabine; Haid, A.

doi:10.1245/aso.2006.08.010

Cited by 11 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Summing up all the other studies, the result is still inconclusive, although larger‐scale studies tended to show that sentinel lymph node sampling was accurate after NAC 2,4,12,14,17,18,23 …”

Section: Discussionmentioning

confidence: 98%

“…SLNB has replaced standard axillary dissection in patients with clinical lymph node negative breast cancer. The standard of care is guided by a rate of SLN identification of 85%, with a false‐negative rate of 5% or less in order to abandon axillary dissection 2,11–14,17,18,23 . For a high SLNB identification rate and low false‐negative rate to be achieved, several situations have been suggested where sentinel lymph node sampling is regarded as relatively contraindicated.…”

Section: Discussionmentioning

confidence: 99%

“…The identification rate ranged from 84 to 93%, while the false‐negative rate ranged from 0 to 33%. Variation of results in these groups of patients has led to further controversy as to whether NAC should be a contraindication for sentinel lymph node sampling biopsy 3,6,10–18 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?

Cheung

Suen

Kwong

2009

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?

Cheung

Suen

Kwong

2009

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Most of the experience with the SLNB after NACT reported in the literature includes small series of patients with clinically negative axilla at initial presentation [34][35][36][37] or contained a mixed group of patients with the majority being node negative [38][39][40][41][42][43][44][45][46][47]. Success in identifying the SLN varied from 72% to 100% (Table 2).…”

Section: Identification Rate and Accuracy Of Sentinel Lymph Node Biopsymentioning

confidence: 99%

Surgical Considerations Following Preoperative Systemic Chemotherapy

Sbaity

Jacobs

2011

Curr Breast Cancer Rep

View full text Add to dashboard Cite

The indications of neoadjuvant chemotherapy for breast cancer are extending to a larger population of breast cancer patients. The aims of this therapy are to transform the cancer to an operable form, downsize the tumor volume to allow a lumpectomy instead of a mastectomy, or to perform an in vivo test of the effect of the treatment on breast cancer in a specific individual. Along with these benefits, there is concern about the safety of lumpectomy and sentinel lymph node biopsy after neoadjuvant chemotherapy. In this review, we discuss the experience of breast conservation therapy after neoadjuvant chemotherapy and the reported recurrence rates in the preserved breasts. An overview of the studies that utilized sentinel lymph node biopsy after neoadjuvant chemotherapy is presented, summarizing the identification rates and false-negative rate.

show abstract

“…In light of these open questions, we previously investigated the feasibility and sensitivity of SNB after primary chemotherapy in a retrospective analysis, employing the data base of the Austrian Sentinel Node Study Group, and achieved an 86% identification rate and a false‐negative rate of 8% (15–17). To substantiate these promising findings in a prospective manner, the combination of SNB and primary chemotherapy was evaluated in a prospective subprotocol of the ABCSG‐Trial 14 with the goal to achieve a false‐negative rate comparable to SNB without primary chemotherapy.…”

mentioning

confidence: 99%

Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14

et al. 2011

Self Cite

View full text Add to dashboard Cite

Over the past years, experience has been increasing with lymphatic mapping and sentinel node biopsy (SNB) after preoperative chemotherapy for breast cancer, with a wide range of results reported in the literature and final conclusions on the diagnostic value and clinical consequences of this sequential approach still missing. Between 1999 and 2002, the Austrian Breast and Colorectal Cancer Study Group (ABCSG) conducted a prospective randomized multicenter trial comparing three versus six preoperative cycles of epirubicin/docetaxel + granulocyte colony-stimulating factor for operable breast cancer. Of the 292 patients recruited to the trial overall, 111 were enrolled in a prospective subprotocol for performing LM and SNB in addition to obligatory axillary lymph node dissection (ALND) after PC. SNB after PC identified at least one sentinel node in 100 of 111 patients (identification rate 90%). In six cases, a false-negative SN was identified, resulting in a false-negative rate of 13% (6 of 47). We only found little correlation between patients and tumor characteristics and the identification rate or false-negative rate. Lymphatic mapping and SNB after primary chemotherapy failed to predict histologic infiltration of the sentinel node with sufficient sensitivity. The routine use of SNB after primary chemotherapy should therefore be discouraged.

show abstract

Sentinel Lymph Node Biopsy After Preoperative Chemotherapy for Breast Cancer: Findings From the Austrian Sentinel Node Study Group

Abstract: The results of SLNB after PC are comparable to the results of SLNB without PC. Further investigation in a prospective setting is warranted to confirm these promising results.

Cited by 11 publications

References 36 publications

Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?

Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?

Surgical Considerations Following Preoperative Systemic Chemotherapy

Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14

Contact Info

Product

Resources

About